Editorial & Opinion
أعرض في EDS

New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors.

التفاصيل البيبلوغرافية
العنوان: New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors.
المؤلفون: Holubar J; Department of Internal Medicine, CHU Nimes, University of Montpellier, 4 rue du Pr Debré, 30900, Nimes, France. jan.holubar@chu-nimes.fr., Arnaud E; Department of Internal Medicine, CHU Nimes, University of Montpellier, 4 rue du Pr Debré, 30900, Nimes, France., Broner J; Department of Internal Medicine, CHU Nimes, University of Montpellier, 4 rue du Pr Debré, 30900, Nimes, France., Pers YM; IRMB, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France., Proust A; Department of Pneumology, CHU Nimes, University of Montpellier, Nimes, France., Goulabchand R; Department of Internal Medicine, CHU Nimes, University of Montpellier, 4 rue du Pr Debré, 30900, Nimes, France.
المصدر: Immunologic research [Immunol Res] 2022 Dec; Vol. 70 (6), pp. 721-724. Date of Electronic Publication: 2022 Sep 20.
نوع المنشور: Letter
اللغة: English
بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 8611087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0755 (Electronic) Linking ISSN: 0257277X NLM ISO Abbreviation: Immunol Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Totawa Nj : Humana Press
Original Publication: Basel ; New York : S. Karger, [c1986-
مواضيع طبية MeSH: Churg-Strauss Syndrome*/diagnosis , Churg-Strauss Syndrome*/drug therapy , Granulomatosis with Polyangiitis*/diagnosis , Granulomatosis with Polyangiitis*/drug therapy, Humans ; Interleukin-5 ; Immunosuppressive Agents
References: Hočevar A, Kopač P, Rotar Ž, Novljan MP, Škrgat S. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab. J Allergy Clin Immunol Pract. 2020;8:2448–9. https://doi.org/10.1016/j.jaip.2020.04.006 . (PMID: 10.1016/j.jaip.2020.04.00632304835)
Caminati M, Maule M, Nalin F, Senna G, Lunardi C. Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma. Rheumatol Oxf Engl. 2021;60:e59-60. https://doi.org/10.1093/rheumatology/keaa572 . (PMID: 10.1093/rheumatology/keaa572)
Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–32. https://doi.org/10.1056/NEJMoa1702079 . (PMID: 10.1056/NEJMoa1702079285146015548295)
Alessandra Vultaggio FN. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020;12:885. https://doi.org/10.4168/aair.2020.12.5.885 . (PMID: 10.4168/aair.2020.12.5.885326385677346991)
Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2021;9:1186-93.e1. https://doi.org/10.1016/j.jaip.2020.09.054 . (PMID: 10.1016/j.jaip.2020.09.05433065367)
Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–100. https://doi.org/10.1002/art.1780330806 . (PMID: 10.1002/art.17803308062202307)
Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:309–14. https://doi.org/10.1136/annrheumdis-2021-221794 . (PMID: 10.1136/annrheumdis-2021-22179435110334)
Canzian A, Venhoff N, Urban ML, Sartorelli S, Ruppert A-M, Groh M, et al. Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European Collaborative Study. Arthritis Rheumatol Hoboken NJ. 2021;73:498–503. https://doi.org/10.1002/art.41534 . (PMID: 10.1002/art.41534)
Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med. 2021;8: 627776. https://doi.org/10.3389/fmed.2021.627776 . (PMID: 10.3389/fmed.2021.627776)
Lyons PA, Peters JE, Alberici F, Liley J, Coulson RMR, Astle W, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10:5120. https://doi.org/10.1038/s41467-019-12515-9 . (PMID: 10.1038/s41467-019-12515-9317195296851141)
Manka LA, Guntur VP, Denson JL, Dunn RM, Dollin YT, Strand MJ, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2021;126:696-701.e1. https://doi.org/10.1016/j.anai.2021.01.035 . (PMID: 10.1016/j.anai.2021.01.035)
Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, et al. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther. 2021;23. https://doi.org/10.1186/s13075-021-02462-6 .
Li W, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil cytoplasmic antibody-associated vasculitis update: genetic pathogenesis. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.624848 .
المشرفين على المادة: 0 (Interleukin-5)
0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20220920 Date Completed: 20221115 Latest Revision: 20221117
رمز التحديث: 20231215
DOI: 10.1007/s12026-022-09317-5
PMID: 36125736
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-0755
DOI:10.1007/s12026-022-09317-5